Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.

Case Report: Infectious prophylaxis in hematological malignancies / Passucci, Mauro; Masucci, Chiara; Paoletti, Francesca; Ielo, Claudia; Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Martelli, Maurizio; Gentile, Giuseppe; Breccia, Massimo. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 13:(2023), p. 1163175. [10.3389/fonc.2023.1163175]

Case Report: Infectious prophylaxis in hematological malignancies

Passucci, Mauro;Masucci, Chiara;Paoletti, Francesca;Ielo, Claudia;Costa, Alessandro;Carmosino, Ida;Scalzulli, Emilia;Martelli, Maurizio;Gentile, Giuseppe;Breccia, Massimo
2023

Abstract

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.
2023
HBV reactivation; myelofibrosis; prophylaxis; ruxolitinib; tenofovir
01 Pubblicazione su rivista::01a Articolo in rivista
Case Report: Infectious prophylaxis in hematological malignancies / Passucci, Mauro; Masucci, Chiara; Paoletti, Francesca; Ielo, Claudia; Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Martelli, Maurizio; Gentile, Giuseppe; Breccia, Massimo. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 13:(2023), p. 1163175. [10.3389/fonc.2023.1163175]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1682379
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact